Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
SLN Stock Forecast 2026-2027
$6.97
Current Price
$329.23M
Market Cap
Buy 5
Hold 0
Sell 1
Wall St Analyst Ratings
Distance to SLN Price Targets
+976.0%
To High Target of $75.00
+273.0%
To Median Target of $26.00
+258.7%
To Low Target of $25.00
SLN Price Momentum
-4.4%
1 Week Change
+21.6%
1 Month Change
+88.4%
1 Year Change
+14.6%
Year-to-Date Change
-17.0%
From 52W High of $8.40
+97.2%
From 52W Low of $3.54
📊 TOP ANALYST CALLS
Did SLN Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Silence Therapeutics is one of their latest high-conviction picks.
Latest SLN Stock Price Targets & Analyst Predictions
Based on our analysis of 8 Wall Street analysts, SLN has a bullish consensus with a median price target of $26.00 (ranging from $25.00 to $75.00). The overall analyst rating is Strong Buy (8.3/10). Currently trading at $6.97, the median forecast implies a 273.0% upside. This outlook is supported by 5 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Patrick R. Trucchio at HC Wainwright & Co., projecting a 976.0% upside. Conversely, the most conservative target is provided by Michael Ulz at Morgan Stanley, suggesting a 258.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SLN Analyst Ratings
5
Buy
0
Hold
1
Sell
SLN Price Target Range
Low
$25.00
Average
$26.00
High
$75.00
Current: $6.97
Latest SLN Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SLN.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2026 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $75.00 |
| Sep 16, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $75.00 |
| Aug 8, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $35.00 |
| Jun 13, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $35.00 |
| Jun 13, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| May 9, 2025 | Chardan Capital | Keay Nakae | Buy | Maintains | $35.00 |
| May 9, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $25.00 |
| May 9, 2025 | Goldman Sachs | Richard Law | Sell | Maintains | $3.00 |
| Mar 7, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Mar 5, 2025 | Morgan Stanley | Michael Ulz | Overweight | Maintains | $45.00 |
| Mar 4, 2025 | Goldman Sachs | Richard Law | Sell | Maintains | $4.00 |
| Mar 4, 2025 | BMO Capital | Kostas Biliouris | Outperform | Maintains | $25.00 |
| Feb 11, 2025 | Goldman Sachs | Richard Law | Sell | Initiates | $6.00 |
| Feb 3, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Jan 29, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Dec 10, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
| Dec 9, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 15, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $75.00 |
| Nov 14, 2024 | Chardan Capital | Keay Nakae | Buy | Maintains | $55.00 |
Silence Therapeutics plc ADR (SLN) Competitors
The following stocks are similar to Silence Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
SLN
Silence Therapeutics
mkt cap
329.23M
Silence Therapeutics plc ADR (SLN) Financial Data
Silence Therapeutics plc ADR has a market capitalization of $329.23M with a P/E ratio of -3.7x. The company generates $839,000 in trailing twelve-month revenue with a 61.5% profit margin.
Revenue growth is +197.2% quarter-over-quarter, while maintaining an operating margin of -3,565.4% and return on equity of -92.6%.
Valuation Metrics
Market Cap
$329.23M
Enterprise Value
$917.73M
P/E Ratio
-3.7x
PEG Ratio
-17.9x
Price/Sales
392.4x
Growth & Margins
Revenue Growth (YoY)
+197.2%
Gross Margin
+64.7%
Operating Margin
-3,565.4%
Net Margin
+61.5%
EPS Growth
-99.9%
Financial Health
Cash/Price Ratio
+7.1%
Current Ratio
9.8x
Debt/Equity
0.3x
ROE
-92.6%
ROA
-29.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Silence Therapeutics plc ADR (SLN) Business Model
About Silence Therapeutics plc ADR
What They Do
Biotechnology company developing RNA interference therapeutics.
Business Model
Silence Therapeutics generates revenue by developing and commercializing RNAi therapeutics, leveraging its proprietary GalNAc targeting platform to improve the efficacy of treatments. The company focuses on partnerships with larger pharmaceutical firms, which can provide funding and resources for its innovative approaches to treating rare diseases and oncology.
Additional Information
The company is positioned at the forefront of RNAi technology, with significant potential to transform the management of genetic disorders. As an ADR, it offers American investors easier access to its shares, enhancing portfolio diversification. Silence Therapeutics is attracting attention for its innovative solutions in the biotechnology sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
116
CEO
Mr. Craig A. Tooman M.B.A.
Country
United Kingdom
IPO Year
1996
Website
www.silence-therapeutics.comSilence Therapeutics plc ADR (SLN) Latest News & Analysis
Latest News
Quick Summary
Silence Therapeutics plc (Nasdaq: SLN) reported Q1 2026 financial results and updates on its mRNAi GOLD™ platform, highlighting ongoing research advancements.
Why It Matters
Silence Therapeutics' financial results and advances in their mRNAi GOLD™ platform signal potential growth and innovation, impacting future stock performance and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Silence Therapeutics (SLN) shares rose with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.
Why It Matters
Silence Therapeutics' share surge with high trading volume indicates heightened investor interest, but uncertain earnings revisions suggest potential volatility ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Silence Therapeutics plc ($SLN) reported Q4 and full-year 2025 financial results, highlighting expedited enrollment in the Phase 2 SANRECO trial for divesiran, with topline results expected in Q3.
Why It Matters
Silence Therapeutics' progress in the Phase 2 SANRECO trial and financial results indicate potential growth and value, influencing market sentiment and investment decisions.
Source: Business Wire
Market Sentiment:
Neutral
Wall Street Analysts See a 467.47% Upside in Silence Therapeutics (SLN): Can the Stock Really Move This High?
2 months ago
Quick Summary
Silence Therapeutics (SLN) has a consensus price target indicating a 467.5% upside potential. Upward earnings estimate revisions suggest possible near-term gains for the stock.
Why It Matters
A 467.5% upside potential suggests significant growth opportunity for Silence Therapeutics (SLN), while positive earnings revisions may indicate imminent stock price increases.
Source: Zacks Investment Research
Market Sentiment:
Positive
Silence Therapeutics Announces Leadership Changes
4 months ago
Quick Summary
Silence Therapeutics plc (NASDAQ: SLN) announced CEO Craig Tooman will leave the company on December 14, 2025. Chairman Iain Ross will assume leadership immediately.
Why It Matters
Leadership changes can signal potential shifts in company strategy or operations, impacting investor confidence and stock performance. Monitoring new leadership's direction is crucial for assessing future prospects.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Silence Therapeutics is progressing its RNAi drug, divesiran, for polycythemia vera, with Phase 2 trial results due in Q3 2026. The company has over $100M in cash, supporting pipeline development through 2028.
Why It Matters
Silence Therapeutics' progress with divesiran and strong cash reserves mitigate financing risks, enhancing its potential for long-term growth and positive clinical outcomes in a niche market.
Source: Seeking Alpha
Market Sentiment:
Negative
Frequently Asked Questions About SLN Stock
What is Silence Therapeutics plc ADR's (SLN) stock forecast for 2026?
Based on our analysis of 8 Wall Street analysts, Silence Therapeutics plc ADR (SLN) has a median price target of $26.00. The highest price target is $75.00 and the lowest is $25.00.
Is SLN stock a good investment in 2026?
According to current analyst ratings, SLN has 5 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $6.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SLN stock?
Wall Street analysts predict SLN stock could reach $26.00 in the next 12 months. This represents a 273.0% increase from the current price of $6.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Silence Therapeutics plc ADR's business model?
Silence Therapeutics generates revenue by developing and commercializing RNAi therapeutics, leveraging its proprietary GalNAc targeting platform to improve the efficacy of treatments. The company focuses on partnerships with larger pharmaceutical firms, which can provide funding and resources for its innovative approaches to treating rare diseases and oncology.
What is the highest forecasted price for SLN Silence Therapeutics plc ADR?
The highest price target for SLN is $75.00 from Patrick R. Trucchio at HC Wainwright & Co., which represents a 976.0% increase from the current price of $6.97.
What is the lowest forecasted price for SLN Silence Therapeutics plc ADR?
The lowest price target for SLN is $25.00 from Michael Ulz at Morgan Stanley, which represents a 258.7% increase from the current price of $6.97.
What is the overall SLN consensus from analysts for Silence Therapeutics plc ADR?
The overall analyst consensus for SLN is bullish. Out of 8 Wall Street analysts, 5 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $26.00.
How accurate are SLN stock price projections?
Stock price projections, including those for Silence Therapeutics plc ADR, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 11, 2026 3:59 AM UTC